Paul Calabresis Career Development Award For Clinical Oncology

保罗·卡拉布雷西斯临床肿瘤学职业发展奖

• 批准号: 8330960
• 负责人: ROMAN PEREZ-SOLER
• 金额: $ 113.4万
• 依托单位: ALBERT EINSTEIN COLLEGE OF MEDICINE
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-09-29 至 2014-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8330960
• 关键词: Advisory Committees; Albert Einstein Cancer Center; Cancer Research Project; Clinical; Clinical Investigator; Clinical Oncology; Clinical Research; Commit; County; Educational process of instructing; Foundations; Funding; Genetic Medicine; Grant; Institutes; Institution; Instruction; Investigation; K-Series Research Career Programs; Leadership; Malignant Neoplasms; Medical center; Medicine; Mentors; Mission; Monitor; NCI Scholars Program; Population; Principal Investigator; Qualifying; Quality of Care; Research; Research Activity; Research Personnel; Research Support; Research Training; Resources; SECTM1 gene; Therapeutic; Training; Training Programs; Translational Research; Underrepresented Minority; Underserved Population; United States National Institutes of Health; Work; anticancer research; base; cancer research center director; career; college; experience; interdisciplinary collaboration; member; patient oriented; professor; programs; racial and ethnic; research facility; translational medicine

DESCRIPTION (provided by applicant): This proposal seeks to support and develop junior clinical investigators in therapeutic cancer research at the Albert Einstein College of Medicine, through a coordinated program of mentoring, didactic course work, collegial interdisciplinary collaboration, and research support. The leadership for this program is integrated with the Albert Einstein Cancer Center (AECC) and Einstein's Institute for Clinical and Translational Research (ICTR), and based on the major commitment of the Institution to the training and mentoring of young clinical investigators. This Paul Calabresi Scholars Program will select highly qualified clinical and translational investigators, including both MDs and PhDs, each developing their careers in patient-oriented clinical and translational research in cancer therapeutics. Didactic course work will be provided through the K30 and other programs, as needed, with an individualized course of instruction determined for each Scholar. Program oversight will be provided by the Principal Investigator, Dr. Roman Perez-Soler, Professor of Medicine and Associate Director for Clinical Research at the AECC. They will be assisted by an Advisory Committee of leaders of Einstein's cancer research programs, who will select Scholars and monitor each Scholar's progress, and a group of External Advisors formed by PI's of Calabresi Grants at other institutions. The Albert Einstein College of Medicine is ideally suited to implement this program. With its strong foundation in NIH supported investigation, it has invested heavily in building its clinical and translational research activities in cancer under the leadership of the AECC Director, Dr. David Goldman. The PI of this KI2 proposal will assist Dr. Goldman in this mission. Einstein's new Dean, Dr. Allen Spiegel, is deeply committed to clinical and translational investigation; as underscored by a comprehensive new Strategic Research Plan and the recent completion of a new research facility, the Center for Genetic and Translational Medicine. Einstein has an outstanding base of clinical and research training programs in cancer, which will provide a pool of highly qualified candidates for this program. Our primary clinical affiliate, Montefiore Medical Center, provides high quality care to a large, traditionally underserved population in the Bronx, a county of over 1.3 million residents, over 80% of whom are members of ethnic/racial underserved minorities. Given its unique combination of clinical and scientific resources, population diversity, research funding, talented trainees, experienced mentors, teaching programs, research facilities, and institutional commitment, Einstein is poised to succeed in this K12 effort.

描述（由申请人提供）：该提案旨在通过协调的指导，教学课程工作，大学跨学科合作和研究支持的计划来支持和发展Albert Einstein医学院治疗癌症研究的初级临床研究者。该计划的领导力与爱因斯坦癌症中心（AECC）和爱因斯坦的临床与转化研究所（ICTR）集成在一起，并基于该机构对培训和指导年轻临床研究人员的主要承诺。该Paul Calabresi学者计划将选择高素质的临床和翻译调查员，包括MDS和PHD，每个研究人员都在癌症治疗剂领导的临床和转化研究中发展其职业。根据需要，将通过K30和其他计划提供教学课程工作，并为每个学者确定个性化的教学课程。计划的监督将由首席研究员Roman Perez-Soler博士，AECC医学教授兼临床研究副总监。爱因斯坦癌症研究计划领导人的咨询委员会将协助他们，他们将选择学者并监控每个学者的进步，以及由其他机构的Calabresi赠款组成的一组外部顾问。阿尔伯特·爱因斯坦医学院非常适合实施该计划。在美国国立卫生研究院（NIH）支持调查的基础上，它在AECC主管David Goldman博士的领导下进行了大量投资，用于在癌症中建立其临床和转化研究活动。该KI2提案的PI将帮助Goldman博士执行此任务。爱因斯坦的新院长艾伦·斯皮格尔（Allen Spiegel）博士深深致力于临床和翻译研究。正如一项全面的新战略研究计划和近期完成的新研究机构（遗传与转化医学中心）的强调。爱因斯坦（Einstein）拥有癌症临床和研究培训计划的出色基础，该计划将为该计划提供一系列高素质的候选人。我们的主要临床会员蒙特菲奥尔医疗中心（Montefiore Medical Center）为布朗克斯（Bronx）的大量传统服务人群提供高质量的护理，该县有超过130万居民，其中80％以上是族裔/种族贫乏少数群体的成员。鉴于其临床和科学资源，人口多样性，研究资金，才华横溢的学员，经验丰富的导师，教学计划，研究设施和机构承诺的独特结合，爱因斯坦有望在这项K12努力中取得成功。